Business
Positive new data demonstrates NEATstiks potential
Positive new data demonstrates NEATstiks potential.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 6716A NetScientific PLC 31 May 2019 \n\nNetScientific plc\n(\"NetScientific\" or the \"Group\")\nNew data demonstrates NEATstik's potential as a rapid bacterial monitoring tool in lung disease\n \nPublished in the European Respiratory Journal\n \nLondon, UK - 31 May 2019 - NetScientific plc (\"NetScientific\", AIM: NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company ProAxsis Limited (\"ProAxsis\") has received positive early data from the BRIDGE[1] study, a major clinical trial funded by the British Lung Foundation (BLF) and the European Respiratory Society (ERS)[2].\n \nIan Postlethwaite, CEO/CFO of NetScientific, said:\n\"This encouraging data published in the renowned European Respiratory Journal demonstrates ProAxsis' ability to monitor bacterial infections in real time in patients suffering from lung diseases. NEATstik® has the potential to provide clinicians with a test identifying those at risk of further exacerbations providing more targeted care. We believe that ProAxsis has the potential to become a significant player in the growing point-of-care respiratory testing market.\"\n \nNetScientific's shareholding in ProAxsis is 56.5% (fully diluted being 54.0%).\n \nThe full text of the announcement released by ProAxsis can be found below.\n \n***\n \nPositive early data from the BRIDGE study, a three-year 1000+ patient study in bronchiectasis funded by the British Lung Foundation (BLF) and the European Respiratory Society (ERS), has been published in the latest edition of the European Respiratory Journal* and demonstrates the potential for NEATstik®, a point-of-care test developed by Belfast-based ProAxsis Limited (www.proaxsis.com), to be used as a rapid primary monitoring tool for lung diseases. \n \nThe pan-EU study is exploring novel biomarkers to demonstrate what they can add to clinical practice. In the publication, the NEATstik® result has been correlated with the severity of lung disease, presence of bacterial infection and risk of future clinical worsening (exacerbations). Furthermore, NEATstik® was able to replicate the results of existing tests for chest infections in people with bronchiectasis within only ten minutes, providing a rapid sample-to-result test that can potentially ...